Based on this, treatment with an antagonist of S1PR1, Siponomid, reduced angiogenesis and tumor growth in a DLBCL mouse model, indicating that S1P-S1PR1-mediated angiogenesis is a potential therapeutic target to subdue DLBCL [365]. This evidence concerns the gene S1PR1 and diffuse large B-cell lymphoma.